Showing results (21-30 of 511) with videos related to

Sort By:
Pageof 52
Acta Biochimica Et Biophysica Sinica|January 11, 2017
Role of norepinephrine in Aβ-related neurotoxicity: dual interactions with Tyr10 and SNK(26-28) of AβMengmeng Liu, Liping Wan, Yannan Bin, et al.
Wei Sheng Wu Xue Bao = Acta Microbiologica Sinica|March 5, 2016
[Molecular cloning and characterization of two oxidative stress related genes from medicinal fungus Polyporus umbellatus]Mengmeng Liu, Chao Song, Yongmei Xing, et al.
Mitochondrial DNA. Part B, Resources|December 28, 2020
Advancement in sequencing the mitochondrial genome of <i>Birmella discoidalisa</i> Wei, 1994 (Hymenoptera: Tenthredinidae) and the phylogenetic classification of FenusiniRuoxuan Wu, Meicai Wei, Mengmeng Liu, et al.
Medcomm|January 3, 2022
Tumor metastasis: Mechanistic insights and therapeutic interventionsMengmeng Liu, Jing Yang, Bushu Xu, et al.
Proceedings. ACM-SIGMOD International Conference on Management of Data|June 30, 2017
Enabling Incremental Query Re-OptimizationMengmeng Liu, Zachary G Ives, Boon Thau Loo
Journal of Agricultural and Food Chemistry|October 23, 2019
Enhanced Coproduction of Cell-Bound Zeaxanthin and Secreted Exopolysaccharides by <i>Sphingobium</i> sp. via Metabolic Engineering and Optimized FermentationMengmeng Liu, Gerhard Sandmann, Feng Chen, et al.
Journal of Chemical Information and Modeling|February 21, 2025
EC2Vec: A Machine Learning Method to Embed Enzyme Commission (EC) Numbers into Vector RepresentationsMengmeng Liu, Xialong Ni, J Ramanujam, et al.
Chinese Medical Journal|January 25, 2024
Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applicationsWenli Zhang, Mengmeng Liu, Wei Li, et al.
Scientific Reports|January 18, 2024
Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effectsMengmeng Liu, Gopal Srivastava, J Ramanujam, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 6, 2026
Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancerMengmeng Liu, Lu Zhong, Mei Dong, et al.
Pageof 52